|
Sign In to gain access to subscriptions and/or personal tools.
|
A comprehensive assessment of the cost of multiple sclerosis in the United States
Kathryn Whetten-Goldstein
Center for Health Policy Research and Education, Box 90253, Duke University, Durham, North Carolina 27708, USA
Frank A Sloan
Center for Health Policy Research and Education, Box 90253, Duke University, Durham, North Carolina 27708, USA, Department of Economics, Duke University, Durham, North Carolina 27708, USA, Fuqua School of Business, Duke University, Durham, North Carolina 27708, USA
Larry B Goldstein
Center for Health Policy Research and Education, Box 90253, Duke University, Durham, North Carolina 27708, USA, Department of Medicine (Neurology), Duke University, Durham, North Carolina 27708, USA, Division of Neurology, Durham Department of Veteran's Affairs Medical Center, Durham, North Carolina, 27710, USA
Elizabeth D Kulas
Center for Health Policy Research and Education, Box 90253, Duke University, Durham, North Carolina 27708, USA, Department of Economics, Duke University, Durham, North Carolina 27708, USA
Comprehensive data on the costs of multiple sclerosis is sparse. We conducted a survey of 606 persons with MS who were members of the National Multiple Sclerosis Society to obtain data on their cost of personal health services, other services, equipment, and earnings. Compensation of such cost in the form of health insurance, income support, and other subsidies was measured. Survey data and data from several secondary sources was used to measure costs incurred by comparable persons without MS. Based on the 1994 data, the annual cost of MS was estimated at over $34 000 per person, translating into a conservative estimate of national annual cost of $6.8 billion, and a total lifetime cost per case of $2.2 million. Major components of cost were earnings loss and informal care. Virtually all persons with MS had health insurance, mostly Medicare/Medicaid. Health insurance covered 51 per cent of costs for services, excluding informal care. On average, compensation for earnings loss was 27 per cent. MS is very costly to the individual, health care system, and society. Much of the cost (57 per cent) is in the form of burdens other than personal health care, including earnings loss, equipment and alternations, and formal and informal care. These costs often are not calculated.
Key Words: multiple sclerosis • cost • United States • insurance • informal care • earnings loss
Multiple Sclerosis, Vol. 4, No. 5,
419-425 (1998)
DOI: 10.1177/135245859800400504
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
G. T. Fujiura
Aging Families and the Demographics of Family Financial Support of Adults With Disabilities
Journal of Disability Policy Studies,
March 1, 2010;
20(4):
241 - 250.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. P. McCabe and E. J. O'Connor
A longitudinal study of economic pressure among people living with a progressive neurological illness
Chronic Illness,
September 1, 2009;
5(3):
177 - 183.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F Khan, L Turner-Stokes, T Stevermuer, and F Simmonds
Multiple sclerosis rehabilitation outcomes: analysis of a national casemix data set from Australia
Multiple Sclerosis,
July 1, 2009;
15(7):
869 - 875.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L.I. Iezzoni, L.H. Ngo, and R.P. Kinkel
Working-age persons with multiple sclerosis and access to disease-modifying medications
Multiple Sclerosis,
January 1, 2008;
14(1):
112 - 122.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Sobocki, M. Pugliatti, K. Lauer, and G. Kobelt
Estimation of the cost of MS in Europe: Extrapolations from a multinational cost study
Multiple Sclerosis,
September 1, 2007;
13(8):
1054 - 1064.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Iezzoni and L. Ngo
Health, disability, and life insurance experiences of working-age persons with multiple sclerosis
Multiple Sclerosis,
May 1, 2007;
13(4):
534 - 546.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. Kobelt, J. Berg, D. Atherly, and O. Hadjimichael
Costs and quality of life in multiple sclerosis: A cross-sectional study in the United States
Neurology,
June 13, 2006;
66(11):
1696 - 1702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin
The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
Multiple Sclerosis,
February 1, 2006;
12(1):
24 - 38.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R Verza, M L L. Carvalho, M A Battaglia, and M M. Uccelli
An interdisciplinary approach to evaluating the need for assistive technology reduces equipment abandonment
Multiple Sclerosis,
February 1, 2006;
12(1):
88 - 93.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Lolli, B. Mulinacci, A. Carotenuto, B. Bonetti, G. Sabatino, B. Mazzanti, A. M. D'Ursi, E. Novellino, M. Pazzagli, L. Lovato, et al.
An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis
PNAS,
July 19, 2005;
102(29):
10273 - 10278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M B Patwardhan, D B Matchar, G P Samsa, D C McCrory, R G Williams, and T T Li
Cost of multiple sclerosis by level of disability: a review of literature
Multiple Sclerosis,
April 1, 2005;
11(2):
232 - 239.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. P. McCabew and M. De Judicibus
The Effects of Economic Disadvantage on Psychological Well-being and Quality of Life among People with Multiple Sclerosis
J Health Psychol,
January 1, 2005;
10(1):
163 - 173.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins
Donepezil improved memory in multiple sclerosis in a randomized clinical trial
Neurology,
November 9, 2004;
63(9):
1579 - 1585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Pozzilli, M Brunetti, A M V Amicosante, C Gasperini, G Ristori, L Palmisano, and M Battaglia
Home based management in multiple sclerosis: results of a randomised controlled trial
J. Neurol. Neurosurg. Psychiatry,
September 1, 2002;
73(3):
250 - 255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Krupp and S. A. Rizvi
Symptomatic therapy for underrecognized manifestations of multiple sclerosis
Neurology,
April 23, 2002;
58(90084):
S32 - 39.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G.C. Pope, C.J. Urato, E.D. Kulas, R. Kronick, and T. Gilmer
Prevalence, expenditures, utilization, and payment for persons with MS in insured populations
Neurology,
January 8, 2002;
58(1):
37 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Gilden
Viruses and Multiple Sclerosis
JAMA,
December 26, 2001;
286(24):
3127 - 3129.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J Buchanan, S. Wang, C. Huang, and D. Graber
Profiles of nursing home residents with multiple sclerosis using the minimum data set
Multiple Sclerosis,
June 1, 2001;
7(3):
189 - 200.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H Carton, R Loos, J Pacolet, K Versieck, and R Vlietinck
A quantitative study of unpaid caregiving in multiple sclerosis
Multiple Sclerosis,
August 1, 2000;
6(4):
274 - 279.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L D Jacobs, K E Wende, C M Brownscheidle, B Apatoff, P K Coyle, A Goodman, M H Gottesman, C V Granger, S J Greenberg, J Herbert, et al.
A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium
Multiple Sclerosis,
October 1, 1999;
5(5):
369 - 376.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Rudick
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol,
September 1, 1999;
56(9):
1079 - 1084.
[Full Text]
[PDF]
|
|
|
|
|
